Cargando…

Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine-resistant myeloid leukemia cells

Cytarabine is a key chemotherapy drug for treating leukemia; however, chemotherapy-induced multidrug resistance is a major cause of therapy failure or tumor recurrence. Current medical treatment strategies still cannot address the issue of multidrug resistance phenotypes in the treatment of leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Yu-Hsin, Yang, Rei-Cheng, Chiou, Shyh-Shin, Shieh, Tzong-Ming, Shih, Yin-Hwa, Lin, Pei-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201441/ https://www.ncbi.nlm.nih.gov/pubmed/34109436 http://dx.doi.org/10.3892/mmr.2021.12204

Ejemplares similares

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells
por: Wang, Shuo-Yu, et al.
Publicado: (2021)

BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer
por: Shu, Xiong, et al.
Publicado: (2021)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Inhibition of mTOR-Dependent Autophagy Sensitizes Leukemic Cells to Cytarabine-Induced Apoptotic Death
por: Bosnjak, Mihajlo, et al.
Publicado: (2014)

BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism
por: Luo, Lifang, et al.
Publicado: (2021)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2
por: Fu, Fei, et al.
Publicado: (2022)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

Modulation of the mTOR Pathway by Curcumin in the Heart of Septic Mice
por: Rattis, Bruna A. C., et al.
Publicado: (2022)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
por: Visser, Nienke, et al.
Publicado: (2021)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2023)

The BCAT1 CXXC Motif Provides Protection against ROS in Acute Myeloid Leukaemia Cells
por: Hillier, James, et al.
Publicado: (2022)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
por: Tsai, Hui‐Jen, et al.
Publicado: (2021)

Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway
por: Zhao, Kai-Hong, et al.
Publicado: (2017)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Deoxyshikonin Inhibits Viability and Glycolysis by Suppressing the Akt/mTOR Pathway in Acute Myeloid Leukemia Cells
por: Wu, Huijuan, et al.
Publicado: (2020)

Evaluation of Sestrin 2, Adiponectin, AMPK, and mTOR Genes Expression in Acute Myeloid Leukemia Patients
por: Abtahi, Seyed Hossein, et al.
Publicado: (2021)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_38llfnc1c6irfberila3go5c37